Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States.
about
Guidance for the prevention and treatment of cancer-associated venous thromboembolismAntithrombotic therapy in patients with thrombocytopenic cancer: outcomes associated with reduced-dose, low-molecular-weight heparin during hospitalization.Controversies in the management of cancer-associated thrombosis.Implementing thrombosis guidelines in cancer patients: a review.Variation in the risk of venous thromboembolism in people with colorectal cancer: a population-based cohort study from EnglandRecurrent hospitalization and healthcare resource use among patients with deep vein thrombosis and pulmonary embolism: findings from a multi-payer analysis.Impact of Time-Varying Treatment Exposures on the Risk of Venous Thromboembolism in Multiple Myeloma.Prospective evaluation of protein C and factor VIII in prediction of cancer-associated thrombosis.The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs.Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) Trial.Incidence and Risk Factors of Thromboembolism with Multiple Myeloma in the Presence of Death as a Competing Risk: An Empirical Comparison of Statistical MethodologiesPredictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer.Venous Thromboembolism in Patients Diagnosed With Lung Cancer.Venous thromboembolism in patients with esophageal or gastric cancer undergoing neoadjuvant chemotherapy.Management of venous thromboembolism in cancer patients: the economic burden of hospitalizations.Direct Medical Costs Attributable to Cancer-Associated Venous Thromboembolism: A Population-Based Longitudinal Study.Predictors of Interventional Treatment Use for Venous Thromboembolism in Cancer Patients.Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria.Thromboembolism in Patients with Bladder Cancer: Incidence, Risk Factors and Prevention.Evaluation of risk factors and assessment models for predicting venous thromboembolism in lung cancer patients.Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants for Venous Thromboembolism Prophylaxis in Patients With Cancer: A Systematic Review and Trade-Off Analysis From 9 Randomized Controlled Trials.
P2860
Q28069131-AFF527DC-7DD5-41EA-B4EC-272E81D9E5EEQ33416407-2EF9ECED-32B0-4605-AE32-1B6FF63FFF46Q33436975-F66968AB-8736-4AF8-BED1-12A95CC3814FQ34463482-EC5CA962-FBC7-4DE3-B756-D52D03AD6034Q34503151-989C9A6D-D48A-44A9-AB7F-30B4D005E9FCQ35232454-E5BC406D-2EBD-457D-A942-DB382BD8B631Q36229918-F4B6E5C0-63E3-4B5A-9CD1-AAB62E68F4AAQ36372812-446FE6A7-205E-4017-9ED4-05A57A82EDE7Q36445585-07537E7B-524C-4F3F-9361-67E0E94ADFEAQ36836396-F3A9C57D-A500-4459-B6C2-9FF0BDBD8ACDQ37069353-1066D5CC-2A79-4097-809F-8CDA9E1F2E91Q38858322-03ECF0FC-1FC4-419B-9DE4-6F98AAD6C219Q38944457-8D9FCA8D-5E4A-455D-A2A2-79A34036E00CQ39017855-08496AE9-1833-4F16-9D4D-A7AB208E25A8Q39794332-8F8AC477-1FDF-463D-80CF-1515358250DBQ39890410-18C22F03-7FF7-41E9-9817-2036A73A7202Q40582932-5D4EF941-FEBE-4363-B9D3-24BC11FF1A39Q47574970-AD06910E-6483-4AC2-816B-9432BB6A0DC0Q55112901-FADBFA20-231C-4871-AB86-E40987FFB64DQ55134553-73B37E57-3303-43E2-897A-3AA957461EEBQ55283799-6195AF1B-A06D-4B41-98E7-41F15AA56A02
P2860
Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Health care costs associated w ...... otherapy in the United States.
@ast
Health care costs associated w ...... otherapy in the United States.
@en
type
label
Health care costs associated w ...... otherapy in the United States.
@ast
Health care costs associated w ...... otherapy in the United States.
@en
prefLabel
Health care costs associated w ...... otherapy in the United States.
@ast
Health care costs associated w ...... otherapy in the United States.
@en
P2093
P2860
P356
P1476
Health care costs associated w ...... otherapy in the United States.
@en
P2093
Alok A Khorana
Gregory C Connolly
Mehul R Dalal
P2860
P304
P356
10.2147/CEOR.S39964
P407
P577
2013-02-13T00:00:00Z